The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer. Similar to other recent CRLs, this decision was made not based on the drug’s ...
Rocket Pharmaceuticals shares have plummeted in value by more than 85% over the last year. Rocket's two lead programs are in an FDA penalty box, one from an unresolved CRL; the other from an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback